← All candidates
One insider buy in the last year — $350.00M in all.
47 filings on record.
IMVTImmunovant, Inc.
NasdaqGS · Healthcare · $7.57B
$36.65
-2.68% · Sep 15
One insider buy in the last year — $350.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 35 sells◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$7.57B
Float
91.8M
44% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Roivant Sciences Ltd.
Bought $350.00M on Dec 12 — 16,666,666 sh @ $21.00, held direct, 15% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
42 more transactions on Pro →Context
Wall St
$46.47 avg target
+26.8% vs today · 17 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.67 act−$0.04
Q4 '25−$0.54 act+$0.15
Q3 '25−$0.65 act+$0.08
Q2 '25−$0.71 act−$0.04
Coverage
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Zacks · 06-19Immunovant Stock Gains 12.4% in a Month: What's Driving It?Zacks · 06-12Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial CommentarySimply Wall St. · 06-05H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial DataInsider Monkey · 06-02
The file stays open
47 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice